Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 7, 2013, Pages 1669-1678

  Heng, Siow Chin ^a   Slavin, Monica A ^b,c   Al Badriyeh, Daoud ^d   Kirsa, Sue ^b   Seymour, John F ^b   Grigg, Andrew ^e   Thursky, Karin ^b,c   Bajel, Ashish ^c   Nation, Roger L ^a   Kong, David C M ^a  

^a MONASH UNIVERSITY   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d Qatar University ^*  (Qatar)

^e AUSTIN HEALTH   (Australia)

Author keywords

AML; Antifungals; Modelling

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; FLUCONAZOLE; POSACONAZOLE; TERBINAFINE; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL EVALUATION; CONSOLIDATION CHEMOTHERAPY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HUMAN; LUNG MYCOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONTE CARLO METHOD; OUTCOME ASSESSMENT; PRESCRIPTION; PSEUDALLESCHERIASIS; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SYSTEMIC MYCOSIS;

EID: 84879474230     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt068     Document Type: Article

References (39)

1. Pagano L, Caira M, Candoni A et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91: 1068-75.
2. Nicolle MC, Benet T, Thiebaut A , et al. Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009. Haematologica 2011; 96: 1685-91.
3. Mahfouz T, Anaissie E. Prevention of fungal infections in the immunocompromised host. Curr Opin Investig Drugs 2003; 4: 974-90.
4. Herbrecht R, Denning DW, Patterson TF , et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
5. Cornely OA, Maertens J, Bresnik M , et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44: 1289-97.
6. Ananda-Rajah MR, Cheng A, Morrissey CO , et al. Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk hematology patients: an economic modeling approach. Antimicrob Agents Chemother 2011; 55: 1953-60.
7. Rotstein C, Bow EJ, Laverdiere M , et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999; 28: 331-40.
8. Vehreschild JJ, Bohme A, Buchheidt D , et al. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect 2007; 55: 445-9.
9. Trifilio SM, Bennett CL, Yarnold PR , et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007; 39: 425-9.
10. Ueda K, Nannya Y, Kumano K , et al. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol 2009; 89: 592-9.
11. Cornely OA, Maertens J, Winston DJ , et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-59.
12. Walsh TJ, Anaissie EJ, Denning DW , et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-60.
13. Cornely OA, Bohme A, Buchheidt D , et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 2009; 94: 113-22.
14. Slavin MA, Heath CH, Thursky KA , et al. Antifungal prophylaxis in adult stem cell transplantation and haematological malignancy. Intern Med J 2008; 38: 468-76.
15. Caira M, Girmenia C, Fadda RM , et al. Invasive fungal infections in patients with acute myeloid leukemia and in those submitted to allogeneic hemopoietic stem cell transplant: who is at highest risk?. Eur J Haematol 2008; 81: 242-3.
16. Bow EJ, Laverdiere M, Lussier N, et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta-analysis of randomized-controlled clinical trials. Cancer 2002; 94: 3230-46.
17. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 2006; 19: 435-47.
18. Chabrol A, Cuzin L, Huguet F, et al. Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia. Haematologica 2010; 95: 996-1003.
19. Vehreschild JJ, Ruping MJ, Wisplinghoff H, et al. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicrob Chemother 2010; 65: 1466-71.
20. Al-Badriyeh D, Slavin M, Liew D, et al. Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia. J Antimicrob Chemother 2010; 65: 1052-61.
21. Collins CD, Ellis JJ, Kaul DR. Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia. Am J Health Syst Pharm 2008; 65: 2237-43.
22. Stam WB, O'Sullivan AK, Rijnders B, et al. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands. Eur J Haematol 2008; 81: 467-74.
23. O'Sullivan AK, Pandya A, Papadopoulos G, et al. Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States. Value Health 2009; 12: 666-73.
24. Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 2007; 25: 5471-89.
25. Pagano L, Caira M, Candoni A, et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 2010; 95: 644-50.
26. Lewis G, Hall P, Eisa N, et al. Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high-dose cytarabine consolidations and thus do not require prophylaxis. Acta Haematol 2010; 124: 206-13.
27. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
28. Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006; 91: 986-9.
29. Sinko J, Csomor J, Nikolova R, et al. Invasive fungal disease in allogeneic hematopoietic stem cell transplant recipients: an autopsy-driven survey. Transpl Infect Dis 2008; 10: 106-9.
30. Slavin MA. Introduction to the updated Australian and New Zealand consensus guidelines for the use of antifungal agents in the haematology/oncology setting, 2008. Intern Med J 2008; 38: 457-67.
31. Health Purchasing Victoria. Health Purchasing Victoria Tender (2010- 2012). http://www.hpv.org.au (3 November 2011, date last accessed).
32. Australian Government of Health and Ageing. National Hospital Cost Data Collection. Round 14 (2009-10) Cost Report Version 6.0x. http://www.health.gov.au/internet/main/publishing.nsf/Content/ADF42B9AC16D4017CA257864000FBD0E/$File/R14CWNatEst_v6x.pdf (21 July 2012, date last accessed).
33. Australian Bureau of Statistics. Consumer Price Index (2012). http://www.ausstats.abs.gov.au/ausstats/meisubs.nsf/0/E292C70FB5AA6FE7CA2579E90017E05D/$File/64010_mar%202012.pdf (21 July 2012, date last accessed).
34. Australian Government of Health and Ageing. Medicare Benefits Schedule Book (2012). http://www.health.gov.au/internet/mbsonline/publishing.nsf/Content/700EAEBE8BC5D5FECA257A0F0017617F/$File/201207-MBS.pdf (21 July 2012, date last accessed).
35. Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358-66.
36. Rogers TR, Slavin MA, Donnelly JP. Antifungal prophylaxis during treatment for haematological malignancies: are we there yet? Br J Haematol 2011; 153: 681-97.
37. Ananda-Rajah MR, Grigg A, Downey MT et al. Comparative clinicaleffectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplasticsyndrome undergoing cytotoxic chemotherapy over a 12-year period.Haematologica 2012; 97: 459-63.
38. Riedel A, Choe L, Inciardi J, et al. Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study. BMC Infect Dis 2007; 7: 70.
39. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-47.